The US FDA has begun an inspection of Cipla's Goa facility, sources told CNBC-TV18.
Goa is Cipla’s largest plant when it comes to the US FDA operations. It is around 20-25 percent of its total US sales in terms of filings, etc.
According to the sources, the inspection began this week. The management of the company maintained that it was a routine general inspection.
In September 2018, during the last inspection, it received two observations, while a year ago, in January 2018, it received around 8 observations which were resolved.